Autolus Therapeutics マネジメント
マネジメント 基準チェック /24
Autolus Therapeuticsの CEO はChris Itinで、 Mar2016年に任命され、 の在任期間は 10.42年です。 の年間総報酬は$ 2.70Mで、 25%給与と75%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.42%を直接所有しており、その価値は$ 2.12M 。経営陣と取締役会の平均在任期間はそれぞれ3年と2.9年です。
主要情報
Chris Itin
最高経営責任者
US$2.7m
報酬総額
| CEO給与比率 | 24.98% |
| CEO在任期間 | 10.4yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 3yrs |
| 取締役会の平均在任期間 | 2.9yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Jun 23
AUTL: Early Treatment Demand And 2026 Margin Shift Could Drive Repricing
Autolus Therapeutics' analyst price targets have shifted, with one firm raising its view to $10 from $9 as analysts point to growing U.S. demand for Aucatyzl and a positive early launch in the UK. Analyst Commentary Recent research on Autolus Therapeutics highlights a mix of optimism and caution as analysts react to the early commercial progress of Aucatyzl and update their valuation work.ナラティブ更新 • Jun 05
AUTL: Early Demand Trends And Profit Outlook Set Up Potential Repricing
Analysts have nudged their average price target on Autolus Therapeutics to around $10, reflecting updated views on Aucatyzl U.S. demand and an early positive read on the UK launch, even as differing research opinions partly offset one another. Analyst Commentary Street research around Autolus Therapeutics is split, with bullish analysts focusing on early commercial traction for Aucatyzl and more cautious voices questioning how much of that optimism is already reflected in valuation.
ナラティブ更新 • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.ナラティブ更新 • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.ナラティブ更新 • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.ナラティブ更新 • Mar 31
AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Seeking Alpha • Mar 27
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking Alpha分析記事 • Feb 03
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Dec 20
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...新しいナラティブ • Aug 17
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.分析記事 • Apr 04
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Seeking Alpha • Mar 04
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Autolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking Alpha分析記事 • Jan 07
Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 21
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking Alpha分析記事 • Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 31
Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 14
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking Alpha分析記事 • Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$289m |
| Dec 31 2025 | US$3m | US$674k | -US$288m |
| Sep 30 2025 | n/a | n/a | -US$225m |
| Jun 30 2025 | n/a | n/a | -US$228m |
| Mar 31 2025 | n/a | n/a | -US$238m |
| Dec 31 2024 | US$2m | US$595k | -US$221m |
| Sep 30 2024 | n/a | n/a | -US$270m |
| Jun 30 2024 | n/a | n/a | -US$234m |
| Mar 31 2024 | n/a | n/a | -US$221m |
| Dec 31 2023 | US$2m | US$551k | -US$208m |
| Sep 30 2023 | n/a | n/a | -US$158m |
| Jun 30 2023 | n/a | n/a | -US$155m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$3m | US$502k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$164m |
| Jun 30 2022 | n/a | n/a | -US$155m |
| Mar 31 2022 | n/a | n/a | -US$146m |
| Dec 31 2021 | US$3m | US$543k | -US$142m |
| Sep 30 2021 | n/a | n/a | -US$143m |
| Jun 30 2021 | n/a | n/a | -US$147m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$4m | US$522k | -US$142m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$127m |
| Dec 31 2019 | US$5m | US$517k | -US$124m |
報酬と市場: Chrisの 総報酬 ($USD 2.70M ) は、 US市場 ($USD 2.41M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Chrisの報酬は増加しましたが、会社は利益を上げていません。
CEO
Chris Itin (62 yo)
10.4yrs
在職期間
US$2,698,699
報酬
Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 10.4yrs | US$2.70m | 0.42% $ 2.1m | |
| Founder | 12yrs | データなし | 0% $ 0 | |
| Senior VP & CFO | 3yrs | データなし | 0% $ 0 | |
| Senior VP & COO | 9.8yrs | データなし | 0.072% $ 365.2k | |
| Senior VP of Finance | less than a year | データなし | データなし | |
| Senior VP & Chief Technology Officer | less than a year | データなし | 0.0089% $ 45.1k | |
| Senior VP of Legal Affairs & General Counsel and Secretary | 4.8yrs | データなし | 0.0069% $ 35.0k | |
| Senior VP & Chief Human Resources Officer | 4.8yrs | データなし | 0% $ 0 | |
| Senior VP & Chief Business Development Officer | 2.6yrs | データなし | 0.0031% $ 15.6k | |
| Senior VP & Chief Development Officer | 1.9yrs | データなし | データなし | |
| Senior VP | less than a year | データなし | データなし | |
| Director of Investor Relations | no data | データなし | データなし |
3.0yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: AUTLの経営陣は 経験豊富 であると考えられます ( 3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 11.8yrs | US$2.70m | 0.42% $ 2.1m | |
| Independent Non-Executive Director | 4.8yrs | US$201.61k | 0% $ 0 | |
| Independent Chairman of the Board | 2.3yrs | US$372.57k | 0% $ 0 | |
| Independent Non-Executive Director | 8.2yrs | US$200.48k | 0.0038% $ 19.0k | |
| Independent Non-Executive Director | 8.2yrs | US$207.90k | 0% $ 0 | |
| Independent Non-Executive Director | 2.6yrs | US$297.60k | 0% $ 0 | |
| Independent Non-Executive Director | 3.2yrs | US$198.91k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$13.45k | データなし | |
| Independent Non-Executive Director | 2.3yrs | US$292.94k | 0% $ 0 | |
| Independent Non-Executive Director | 2.7yrs | US$269.16k | 0% $ 0 |
2.9yrs
平均在職期間
59yo
平均年齢
経験豊富なボード: AUTLの 取締役会 は 経験豊富 ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/06 09:00 |
| 終値 | 2026/08/06 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Autolus Therapeutics plc 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17
| アナリスト | 機関 |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |